BCL2L1 and type 1 diabetes mellitus: For this, either AAV-based gene therapy [206] or CRISPR/dCas9-based enhancer activation [207] could be employed to induce Bcl-xL overexpression in human islets, which could subsequently be transplanted into individuals with T1D.